JPWO2020210512A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020210512A5 JPWO2020210512A5 JP2021559904A JP2021559904A JPWO2020210512A5 JP WO2020210512 A5 JPWO2020210512 A5 JP WO2020210512A5 JP 2021559904 A JP2021559904 A JP 2021559904A JP 2021559904 A JP2021559904 A JP 2021559904A JP WO2020210512 A5 JPWO2020210512 A5 JP WO2020210512A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr
- complementarity determining
- chain complementarity
- determining regions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 111
- 239000012634 fragment Substances 0.000 claims 60
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 claims 22
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 claims 22
- 238000000034 method Methods 0.000 claims 22
- 210000004027 cell Anatomy 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 102000000905 Cadherin Human genes 0.000 claims 6
- 108050007957 Cadherin Proteins 0.000 claims 6
- 210000000822 natural killer cell Anatomy 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 102100029758 Cadherin-4 Human genes 0.000 claims 3
- 108050000637 N-cadherin Proteins 0.000 claims 3
- 108010086890 R-cadherin Proteins 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000002452 interceptive effect Effects 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 claims 2
- 206010023791 Large granular lymphocytosis Diseases 0.000 claims 2
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 claims 2
- 238000011360 adjunctive therapy Methods 0.000 claims 2
- 201000008319 inclusion body myositis Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962831713P | 2019-04-09 | 2019-04-09 | |
| US62/831,713 | 2019-04-09 | ||
| PCT/US2020/027498 WO2020210512A1 (en) | 2019-04-09 | 2020-04-09 | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022528721A JP2022528721A (ja) | 2022-06-15 |
| JPWO2020210512A5 true JPWO2020210512A5 (he) | 2023-04-17 |
| JP7560476B2 JP7560476B2 (ja) | 2024-10-02 |
Family
ID=72748720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559904A Active JP7560476B2 (ja) | 2019-04-09 | 2020-04-09 | キラー細胞レクチン様受容体サブファミリーｇメンバー１（ｋｌｒｇ１）除去抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11180561B2 (he) |
| EP (1) | EP3952999A4 (he) |
| JP (1) | JP7560476B2 (he) |
| KR (1) | KR20210150506A (he) |
| CN (1) | CN114040800B (he) |
| AU (1) | AU2020272939A1 (he) |
| BR (1) | BR112021019128A2 (he) |
| CA (1) | CA3136625A1 (he) |
| IL (1) | IL287044A (he) |
| MX (1) | MX2021012171A (he) |
| SG (1) | SG11202110610VA (he) |
| WO (1) | WO2020210512A1 (he) |
| ZA (1) | ZA202107414B (he) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022056289A1 (en) * | 2020-09-11 | 2022-03-17 | National Jewish Health | Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells |
| WO2022204529A1 (en) * | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
| US20240174754A1 (en) * | 2021-03-26 | 2024-05-30 | Abcuro, Inc. | Anti-klrg1 antibodies |
| MX2024001277A (es) * | 2021-07-26 | 2024-02-15 | Abcuro Inc | Anticuerpos agotadores del miembro 1 de la subfamilia g del receptor tipo lectina de celulas asesinas (klrg1). |
| WO2024072872A2 (en) * | 2022-09-27 | 2024-04-04 | The Brigham And Women's Hospital, Inc. | Klrg1 signalling therapy for infectious disease |
| WO2025147544A1 (en) | 2024-01-02 | 2025-07-10 | Abcuro, Inc. | Methods of treating inclusion body myositis (ibm) |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| AU2001245838A1 (en) | 2000-03-17 | 2001-10-03 | Gemini Science, Inc. | Soluble mast cell function associated antigen (mafa) pharmaceutical compositionsand methods of making and using them |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| JP3536039B2 (ja) * | 2001-05-08 | 2004-06-07 | 独立行政法人 科学技術振興機構 | Ｈｔｌｖ−ｉ腫瘍に対する抗腫瘍抗原又はその抗原エピトープ |
| GB0114107D0 (en) * | 2001-06-09 | 2001-08-01 | Medical Res Council | Respiratory syncytial virus |
| BRPI0808227A2 (pt) | 2007-03-14 | 2014-07-08 | Taligen Therapeutics Inc | Anticorpo humanizado anti-fator b |
| ES2978496T3 (es) | 2009-07-08 | 2024-09-13 | Kymab Ltd | Modelos animales y moléculas terapéuticas |
| JP2012025694A (ja) * | 2010-07-23 | 2012-02-09 | Asahi Kasei Kuraray Medical Co Ltd | 癌治療剤 |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| MX2014011646A (es) * | 2012-03-28 | 2015-02-24 | Genentech Inc | Anticuerpos idiotipos anti citomegalovirus humano (anti-hmcv) y sus usos. |
| WO2016013672A1 (ja) * | 2014-07-25 | 2016-01-28 | 国立研究開発法人理化学研究所 | メモリーインバリアントｎｋｔ細胞マーカー |
| AU2016356877A1 (en) * | 2015-11-17 | 2018-05-10 | Glaxosmithkline Intellectual Property Development Limited | Binding agonists for treatment of neurological and other disorders |
| UA126115C2 (uk) | 2016-03-08 | 2022-08-17 | Янссен Байотек, Інк. | Антитіло до gitr |
| JP2019518791A (ja) | 2016-06-03 | 2019-07-04 | ザ・ブリガム・アンド・ウィメンズ・ホスピタルＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ | Ｋｌｒｇ１シグナリングセラピー |
| EP3512553A4 (en) * | 2016-09-16 | 2021-01-06 | The Brigham and Women's Hospital, Inc. | KLRG1 EXHAUST THERAPY |
| US20210002373A1 (en) * | 2018-03-01 | 2021-01-07 | Nextcure, Inc. | KLRG1 Binding Compositions and Methods of Use Thereof |
-
2020
- 2020-04-09 KR KR1020217036417A patent/KR20210150506A/ko active Pending
- 2020-04-09 SG SG11202110610VA patent/SG11202110610VA/en unknown
- 2020-04-09 WO PCT/US2020/027498 patent/WO2020210512A1/en active Search and Examination
- 2020-04-09 EP EP20788331.5A patent/EP3952999A4/en active Pending
- 2020-04-09 MX MX2021012171A patent/MX2021012171A/es unknown
- 2020-04-09 BR BR112021019128A patent/BR112021019128A2/pt unknown
- 2020-04-09 JP JP2021559904A patent/JP7560476B2/ja active Active
- 2020-04-09 US US16/844,747 patent/US11180561B2/en active Active
- 2020-04-09 AU AU2020272939A patent/AU2020272939A1/en active Pending
- 2020-04-09 CA CA3136625A patent/CA3136625A1/en active Pending
- 2020-04-09 CN CN202080036935.9A patent/CN114040800B/zh active Active
-
2021
- 2021-10-01 ZA ZA2021/07414A patent/ZA202107414B/en unknown
- 2021-10-06 IL IL287044A patent/IL287044A/he unknown
- 2021-10-20 US US17/506,313 patent/US12139541B2/en active Active
-
2024
- 2024-09-12 US US18/883,109 patent/US20250101114A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504723A5 (he) | ||
| RU2008149918A (ru) | Антитела к nkg2a и их применения | |
| RU2018100820A (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА И АНТИТЕЛА С СОЗРЕВШЕЙ АФФИННОСТЬЮ ПРОТИВ FcRH5 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| TWI769537B (zh) | 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途 | |
| JP2016510002A5 (he) | ||
| JP2017536341A5 (he) | ||
| AR040046A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
| MX2013009130A (es) | Tratamiento de la osteoartritis y del dolor. | |
| CN112119099A (zh) | 三特异性抗原结合蛋白 | |
| KR20130010123A (ko) | ＴＮＦ-α 결합 단백질 | |
| RU2012107286A (ru) | Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2 | |
| JPWO2019234220A5 (he) | ||
| JPWO2022046944A5 (he) | ||
| US20230192861A1 (en) | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof | |
| AR122761A1 (es) | Moléculas de unión a antígeno biespecíficas anti-cd3 / anti-cd28 | |
| RU2022108410A (ru) | Терапевтические антитела против лиганда cd40 | |
| WO2022166940A1 (en) | Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors | |
| RU2007118670A (ru) | Ангиопоэтин-2-специфические связывающие агенты | |
| RU2008140947A (ru) | Антитела к egfl7 и способы их применения | |
| JPWO2020210512A5 (he) | ||
| JPWO2020180819A5 (he) | ||
| KR20220119393A (ko) | 약학 조성물, 이의 제조 방법 및 이의 용도 | |
| CA2538725A1 (en) | Nogo-a binding molecules and pharmaceutical use thereof | |
| JPWO2020123664A5 (he) | ||
| TWI825687B (zh) | 抗ｃｘｃｒ２抗體及其用途 |